Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 21 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

14%

3 trials in Phase 3/4

Results Transparency

20%

3 of 15 completed with results

Key Signals

3 with results100% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (1)
P 1 (7)
P 2 (5)
P 3 (3)

Trial Status

Completed15
Not Yet Recruiting2
Recruiting2
Unknown1
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 15 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT07254208Enrolling By InvitationPrimary

A Long-term Observational Study in Participants Who Have Received PBGENE-HBV

NCT03664518Phase 2Completed

to Evaluate the Efficacy and Safety of Eltrombopag for Immune Thrombocytopenia With Chronic HBV Infection

NCT07179575Phase 1RecruitingPrimary

Study of LW231 in Participants With Chronic Hepatitis B

NCT06887036Phase 2RecruitingPrimary

Methylene Blue Treatment of Chronic Hepatitis B Virus Infection

NCT06990438Not Yet Recruiting

Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B

NCT06896630Not Yet Recruiting

Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B

NCT03903796Phase 3CompletedPrimary

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

NCT02836249Phase 3Completed

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

NCT05734807Phase 2CompletedPrimary

A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

NCT02836236Phase 3Completed

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

NCT04147208Phase 2CompletedPrimary

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

NCT05851261Phase 1CompletedPrimary

Study to Evaluate the Safety, Tolerance, Pharmacokinetics Characteristics of PA3670 Tablets in Chinese Healthy Subjects

NCT06029634CompletedPrimary

Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients

NCT05792761Not ApplicableUnknownPrimary

A Study on Antiviral Treatment of Chronic Hepatitis B in Children

NCT05019040Phase 1CompletedPrimary

Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

NCT05542979Phase 1CompletedPrimary

A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection

NCT05468060Phase 1CompletedPrimary

Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy Subjects

NCT04470388Phase 1CompletedPrimary

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

NCT04008004Phase 1CompletedPrimary

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

NCT03909191CompletedPrimary

Serum HBV RNA Value on Chronic Hepatitis B Virus Infection Manage

Scroll to load more

Research Network

Activity Timeline